Pioneering transformative breakthroughs that redefine discovery.
MISSION
Pioneering functional immunomics to uncover key immune cell pathways that will shape the future of next-generation immunotherapies for cancer and autoimmune diseases.
ABOUT
We approach discovery challenges, such as identifying the unique pathways that regulate immune cytotoxicity in specific cancers, with our proprietary Intelligent Design™ technology, empowered by AI-driven bioinformatics and led by our mission focused team of scientists, engineers, and clinicians.
Approach
PRECISION. PERSONALIZATION. INNOVATION.
At Feromics, we combine our Intelligent Design™ technology with deep biological insights to develop highly effective immunotherapy treatments. Our approach begins with the creation of proprietary libraries of interacting disease and immune cells divided by phenotypic functionalities such as cancer cell killing. Through the integration of AI and deep learning, we uncover novel, therapeutically relevant function-specific pathways that drive our capabilities and solutions in multiple areas, including the design and optimization of CAR-T and CAR-Treg constructs to enhance efficacy and safety in immunotherapies. Selection of donors for allogeneic immunotherapies ensures donor cells provide high therapeutic efficacy and patient compatibility. Derisking preclinical and clinical development streamlines the transition from research to clinical application and tailoring treatments to individual patient based on their unique immune profiles for improved therapeutic outcomes.
Partnerships
BETTER TOGETHER
Learn how our Intelligent Design™ technology and mission-focused team can empower discovery through functional immunomics to uncover key immune cell pathways and help expand and strengthen immunotherapy pipelines.
Grants
SUPPORTING OUR RESEARCH
Awarded up to $4M 3-year contract from the Advanced Research Projects Agency for Health (ARPA-H) to develop a precision medicine technology to improve patient treatment selection in cancer immunotherapy.
Under Contract No. 75N91024C00036 the Advanced Research Projects Agency for Health (ARPA-H), part of the Department of Health and Human Services, supports cutting-edge transformative biomedical and health breakthroughs.
OUR STORY
The story of Feromics began at the research laboratory of Professor Tania Konry at Northeastern University, where a team of engineers, biologists, and computer scientists developed a novel biotechnology that drives single-cell assay models for cancer and autoimmune disease. This breakthrough effort began in 2013 and resulted in over 52 scientific papers and patents, and collaborations with leading pharmaceutical companies. In 2022, Dr. Shai Schubert joined Dr. Konry as CEO to co-found Feromics, bringing the strategy, vision and leadership that drives our mission to develop innovative treatments that drive impactful, life-changing outcomes.